Colorectal malignant tumor
Conditions
Interventions
Observation group:none
Sponsors
Ningbo Medical Centre Lihuili Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Diagnosis and source: Confirmed by pathology as colorectal cancer, planned for radical or palliative surgical resection; 2.Sample availability and quality requirements: able to complete organizational processing within the specified time window; The organizational quantity meets the minimum requirements for two-photon imaging and spatial transcriptome detection. 3.Integrity of clinical data: Core clinical and pathological information can be obtained, including age, gender, tumor location (colon/rectum, left and right colon), TNM staging, differentiation degree, presence of lymphatic/vascular/nerve invasion, and treatment information (whether neoadjuvant therapy is used, etc.). 4.Informed consent: The subject or their legal representative signs a written informed consent form for the collection of tissue samples and scientific research use (including relevant clauses for genetic testing/transcriptome testing, if applicable).
Exclusion criteria
Exclusion criteria: 1. Pathological type does not match the main cohort: Postoperative pathology indicates predominantly non-adenocarcinoma types (such as neuroendocrine tumors, lymphoma, GIST, squamous cell carcinoma, etc.) and the study protocol is not pre-included. 2. Therapeutic factors causing significant changes in transcriptome/tissue structure that are unsuitable for primary analysis: preoperative neoadjuvant chemoradiotherapy, immunotherapy, or targeted therapy resulting in high tissue necrosis rates, minimal tumor remnants, or marked RNA quality impairment. 3. Sample quality does not meet standards (1) Post-ex vivo tissue processing exceeds the SOP time, or fixation/freezing/preservation conditions do not meet requirements; (2) Severe tissue autolysis, mechanical compression, electrocautery burns, unable to meet two-photon imaging or spatial transcriptome detection requirements; (3) RNA quality or sequencing/library quality control is substandard (e.g., RIN/DV200/spatial transcription platform quality control indicators not met—you can use the phrase "determined according to platform quality control standards" to avoid writing down the values); (4) Imaging data are severely artificial, have insufficient signal-to-noise ratio, or cannot achieve cross-modal registration (such as slicing folding, detachment, strong background fluorescence, etc.), and cannot be re-sampled. 4. Insufficient sample representativeness: (1) Only a very small amount of tissue can be obtained, and cannot simultaneously meet (or at least meet one) minimum requirements for two-photon imaging and spatial transcriptome detection; (2) The tumor tissue contains too few tumor cells (for example, almost all are necrotic or inflammatory exudation), and pathological assessment does not provide analytical significance. 5. Explanation of the impact of other tumors or special circumstances: (1) Combined with other active malignant tumors (unless in a stable period after cure and allowed by the regimen); (2) Clearly identify tumors related to genetic syndromes (such as Lynch, FAP). If you do not plan to include (you can write "excluding those without preset stratification"); If included in the plan, it should be changed to recording and layered).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Accuracy of predicting gene expression space; | — |
Countries
China
Contacts
Public ContactJiazi Yu
Ningbo Medical Centre Lihuili Hospital
Outcome results
None listed